X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop new drug products by leveraging MerDury’s StackDose platform which has the technology to generate new products with unique fast-release properties when it is administered orally.
Lead Product(s): Undislcosed
Therapeutic Area: Technology Product Name: Undislcosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: Merdury Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 06, 2023
Details:
BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer has been approved and the study can proceed.
Lead Product(s): BLEX 404,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: ABV-1519
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: ABVC BioPharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
BioKey has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer, RGC-1502 for the treatment of pancreatic cancer and RGC 1503 for the treatment of colorectal cancer.
Lead Product(s): RGC-1501
Therapeutic Area: Oncology Product Name: RGC-1501
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rgene Corporation
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Partnership June 21, 2022
Details:
Under the terms of the contract, BioKey will receive payments over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained in connection with CEN501 and NEU001, through completion of Phase II clinical studies.
Lead Product(s): CEN501
Therapeutic Area: Immunology Product Name: CEN501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeuCen BioMed
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
